Concepts (242)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 14 | 2016 | 331 | 1.190 |
Why?
|
| Neoplasms | 7 | 2023 | 1240 | 0.930 |
Why?
|
| Peritoneal Neoplasms | 3 | 2015 | 24 | 0.910 |
Why?
|
| General Surgery | 2 | 2023 | 191 | 0.790 |
Why?
|
| Societies, Medical | 1 | 2023 | 338 | 0.740 |
Why?
|
| Preoperative Care | 3 | 2019 | 180 | 0.660 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2018 | 32 | 0.580 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2018 | 88 | 0.560 |
Why?
|
| Breast Neoplasms | 3 | 2023 | 1118 | 0.560 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 582 | 0.550 |
Why?
|
| Potassium Iodide | 1 | 2016 | 4 | 0.540 |
Why?
|
| Graves Disease | 1 | 2016 | 15 | 0.530 |
Why?
|
| Thyroidectomy | 1 | 2016 | 31 | 0.530 |
Why?
|
| Pancreatectomy | 7 | 2016 | 96 | 0.520 |
Why?
|
| Frailty | 1 | 2018 | 124 | 0.510 |
Why?
|
| Genes, p16 | 1 | 2015 | 6 | 0.490 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2015 | 12 | 0.490 |
Why?
|
| Antineoplastic Agents | 4 | 2015 | 631 | 0.480 |
Why?
|
| Colorectal Neoplasms | 2 | 2015 | 263 | 0.470 |
Why?
|
| Hyperthermia, Induced | 2 | 2014 | 18 | 0.440 |
Why?
|
| Immunotherapy, Active | 1 | 2012 | 3 | 0.410 |
Why?
|
| Trisaccharides | 1 | 2012 | 9 | 0.410 |
Why?
|
| Cancer Vaccines | 1 | 2012 | 46 | 0.390 |
Why?
|
| Humans | 45 | 2023 | 59356 | 0.360 |
Why?
|
| Database Management Systems | 1 | 2010 | 17 | 0.340 |
Why?
|
| Female | 30 | 2023 | 30704 | 0.310 |
Why?
|
| Retrospective Studies | 17 | 2023 | 6071 | 0.300 |
Why?
|
| Carcinoma | 1 | 2009 | 115 | 0.300 |
Why?
|
| Genetic Therapy | 1 | 2015 | 733 | 0.300 |
Why?
|
| Multicenter Studies as Topic | 2 | 2007 | 130 | 0.290 |
Why?
|
| Artificial Intelligence | 1 | 2010 | 155 | 0.290 |
Why?
|
| Adenoma | 2 | 2007 | 64 | 0.280 |
Why?
|
| Liver Neoplasms | 2 | 2009 | 277 | 0.270 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 406 | 0.250 |
Why?
|
| Male | 27 | 2023 | 27738 | 0.240 |
Why?
|
| Radiopharmaceuticals | 2 | 2021 | 180 | 0.240 |
Why?
|
| Palliative Care | 1 | 2007 | 215 | 0.240 |
Why?
|
| Injections, Intralesional | 2 | 2016 | 12 | 0.230 |
Why?
|
| Hepatectomy | 2 | 2019 | 60 | 0.230 |
Why?
|
| Middle Aged | 24 | 2019 | 16317 | 0.230 |
Why?
|
| Adult | 12 | 2023 | 15669 | 0.230 |
Why?
|
| Treatment Outcome | 11 | 2016 | 5284 | 0.230 |
Why?
|
| Hyperparathyroidism | 1 | 2003 | 7 | 0.220 |
Why?
|
| Parathyroid Neoplasms | 1 | 2003 | 4 | 0.220 |
Why?
|
| Parathyroidectomy | 1 | 2003 | 6 | 0.220 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2007 | 677 | 0.210 |
Why?
|
| Catheter Ablation | 1 | 2005 | 145 | 0.210 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2003 | 33 | 0.210 |
Why?
|
| Intestinal Obstruction | 1 | 2023 | 49 | 0.210 |
Why?
|
| New England | 1 | 2023 | 267 | 0.210 |
Why?
|
| History, 21st Century | 1 | 2023 | 162 | 0.200 |
Why?
|
| Melanoma | 2 | 2016 | 329 | 0.200 |
Why?
|
| History, 20th Century | 1 | 2023 | 223 | 0.200 |
Why?
|
| Aged | 18 | 2016 | 13416 | 0.190 |
Why?
|
| Laparoscopy | 3 | 2021 | 427 | 0.190 |
Why?
|
| Lung | 2 | 2023 | 919 | 0.190 |
Why?
|
| Hernia, Hiatal | 1 | 2021 | 26 | 0.180 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2015 | 106 | 0.180 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 22 | 0.180 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 44 | 0.180 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 2337 | 0.180 |
Why?
|
| Risk Assessment | 3 | 2021 | 1921 | 0.180 |
Why?
|
| Postoperative Complications | 4 | 2021 | 1202 | 0.170 |
Why?
|
| Survival Rate | 7 | 2010 | 802 | 0.170 |
Why?
|
| Lumbar Vertebrae | 1 | 2021 | 137 | 0.170 |
Why?
|
| Spinal Fusion | 1 | 2021 | 124 | 0.160 |
Why?
|
| Postoperative Hemorrhage | 1 | 2019 | 37 | 0.150 |
Why?
|
| Vaccination | 1 | 2021 | 334 | 0.150 |
Why?
|
| Injections, Intraperitoneal | 2 | 2015 | 46 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2005 | 1526 | 0.150 |
Why?
|
| Aged, 80 and over | 9 | 2016 | 5128 | 0.150 |
Why?
|
| Caregivers | 1 | 2021 | 231 | 0.150 |
Why?
|
| Pandemics | 1 | 2023 | 615 | 0.150 |
Why?
|
| Hospital Mortality | 7 | 2010 | 841 | 0.150 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2016 | 62 | 0.140 |
Why?
|
| Mice, Nude | 2 | 2015 | 258 | 0.140 |
Why?
|
| Adenocarcinoma | 2 | 2010 | 323 | 0.140 |
Why?
|
| Lymphoscintigraphy | 1 | 2016 | 6 | 0.130 |
Why?
|
| Adrenalectomy | 2 | 2010 | 24 | 0.130 |
Why?
|
| Sentinel Lymph Node | 1 | 2016 | 9 | 0.130 |
Why?
|
| Methylene Blue | 1 | 2016 | 22 | 0.130 |
Why?
|
| Recovery of Function | 1 | 2018 | 270 | 0.130 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2016 | 38 | 0.130 |
Why?
|
| Blood Loss, Surgical | 1 | 2016 | 57 | 0.130 |
Why?
|
| Operative Time | 1 | 2016 | 76 | 0.130 |
Why?
|
| Coloring Agents | 1 | 2016 | 53 | 0.130 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2016 | 7 | 0.130 |
Why?
|
| Single-Blind Method | 1 | 2016 | 136 | 0.130 |
Why?
|
| Colonic Neoplasms | 2 | 2010 | 215 | 0.130 |
Why?
|
| Glycolipids | 1 | 2016 | 44 | 0.130 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 2373 | 0.130 |
Why?
|
| Pancreas, Exocrine | 1 | 2016 | 12 | 0.130 |
Why?
|
| Databases, Factual | 3 | 2016 | 813 | 0.130 |
Why?
|
| Pancreatitis, Chronic | 1 | 2015 | 19 | 0.120 |
Why?
|
| Diet | 1 | 2019 | 497 | 0.120 |
Why?
|
| Neoplasm Transplantation | 1 | 2015 | 161 | 0.120 |
Why?
|
| Neoplasm Staging | 5 | 2010 | 452 | 0.120 |
Why?
|
| Random Allocation | 1 | 2015 | 192 | 0.120 |
Why?
|
| Adenoviridae | 1 | 2015 | 117 | 0.120 |
Why?
|
| Genetic Testing | 1 | 2015 | 126 | 0.120 |
Why?
|
| Islets of Langerhans | 1 | 2016 | 271 | 0.110 |
Why?
|
| Hospital Information Systems | 1 | 2013 | 11 | 0.110 |
Why?
|
| United States | 11 | 2023 | 7390 | 0.110 |
Why?
|
| Biomarkers, Tumor | 2 | 2008 | 461 | 0.110 |
Why?
|
| Risk Factors | 8 | 2021 | 4984 | 0.100 |
Why?
|
| Combined Modality Therapy | 2 | 2014 | 355 | 0.100 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2012 | 3 | 0.100 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2012 | 51 | 0.100 |
Why?
|
| MCF-7 Cells | 1 | 2012 | 65 | 0.100 |
Why?
|
| Apoptosis | 2 | 2015 | 1032 | 0.100 |
Why?
|
| Quality of Life | 2 | 2010 | 1137 | 0.100 |
Why?
|
| Autoantibodies | 1 | 2012 | 172 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 404 | 0.090 |
Why?
|
| Quality of Health Care | 2 | 2021 | 510 | 0.090 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 147 | 0.090 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 1370 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2013 | 256 | 0.090 |
Why?
|
| Methionine | 1 | 2010 | 53 | 0.090 |
Why?
|
| Electronic Health Records | 1 | 2013 | 342 | 0.090 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2010 | 27 | 0.090 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2010 | 15 | 0.090 |
Why?
|
| Sarcoma | 1 | 2010 | 37 | 0.080 |
Why?
|
| Inpatients | 2 | 2010 | 291 | 0.080 |
Why?
|
| Patient Simulation | 1 | 2010 | 67 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 72 | 0.080 |
Why?
|
| Incidence | 3 | 2021 | 1237 | 0.080 |
Why?
|
| Infusions, Parenteral | 1 | 2009 | 21 | 0.080 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2009 | 16 | 0.080 |
Why?
|
| Mitomycin | 1 | 2009 | 24 | 0.080 |
Why?
|
| Digestive System Diseases | 1 | 2009 | 14 | 0.080 |
Why?
|
| SEER Program | 4 | 2010 | 66 | 0.080 |
Why?
|
| Carcinoma, Papillary | 1 | 2009 | 35 | 0.080 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2009 | 30 | 0.080 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2009 | 41 | 0.080 |
Why?
|
| Cisplatin | 1 | 2009 | 119 | 0.080 |
Why?
|
| Genetic Vectors | 1 | 2015 | 808 | 0.080 |
Why?
|
| Neuroendocrine Tumors | 1 | 2009 | 21 | 0.080 |
Why?
|
| Pancreatitis | 1 | 2009 | 95 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 1 | 2009 | 250 | 0.080 |
Why?
|
| Sp1 Transcription Factor | 1 | 2008 | 21 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2010 | 332 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 300 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2016 | 58 | 0.070 |
Why?
|
| Emotions | 1 | 2010 | 214 | 0.070 |
Why?
|
| Prognosis | 4 | 2019 | 1600 | 0.070 |
Why?
|
| Sickness Impact Profile | 1 | 2007 | 47 | 0.070 |
Why?
|
| Hemorrhage | 1 | 2009 | 260 | 0.070 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2010 | 40 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 1561 | 0.070 |
Why?
|
| Gastrectomy | 1 | 2007 | 37 | 0.070 |
Why?
|
| Thyroid Neoplasms | 1 | 2007 | 71 | 0.070 |
Why?
|
| Stomach Neoplasms | 1 | 2007 | 69 | 0.070 |
Why?
|
| Curriculum | 1 | 2010 | 558 | 0.070 |
Why?
|
| Attitude of Health Personnel | 1 | 2010 | 550 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2009 | 326 | 0.060 |
Why?
|
| Communication | 1 | 2010 | 546 | 0.060 |
Why?
|
| Algorithms | 1 | 2010 | 976 | 0.060 |
Why?
|
| Radiography, Interventional | 1 | 2005 | 72 | 0.060 |
Why?
|
| Quality Indicators, Health Care | 1 | 2007 | 332 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 441 | 0.060 |
Why?
|
| Patient Satisfaction | 1 | 2007 | 412 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2010 | 1151 | 0.060 |
Why?
|
| Mice | 2 | 2015 | 10289 | 0.050 |
Why?
|
| Time Factors | 3 | 2019 | 3617 | 0.050 |
Why?
|
| Animals | 4 | 2015 | 19648 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2003 | 121 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2016 | 75 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2010 | 746 | 0.050 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2003 | 98 | 0.050 |
Why?
|
| Pheochromocytoma | 1 | 2002 | 24 | 0.050 |
Why?
|
| RNA-Binding Proteins | 1 | 2005 | 385 | 0.050 |
Why?
|
| Surgical Mesh | 1 | 2021 | 58 | 0.050 |
Why?
|
| Esophagectomy | 1 | 2021 | 45 | 0.040 |
Why?
|
| Herniorrhaphy | 1 | 2021 | 69 | 0.040 |
Why?
|
| Patient Selection | 1 | 2023 | 464 | 0.040 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2021 | 91 | 0.040 |
Why?
|
| Research Design | 1 | 2023 | 555 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2010 | 2374 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2021 | 133 | 0.040 |
Why?
|
| Recurrence | 1 | 2021 | 603 | 0.040 |
Why?
|
| Postoperative Period | 2 | 2009 | 127 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 937 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 375 | 0.040 |
Why?
|
| Sex Distribution | 2 | 2007 | 244 | 0.030 |
Why?
|
| Age Distribution | 2 | 2007 | 249 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2021 | 618 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 1122 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 74 | 0.030 |
Why?
|
| Comorbidity | 2 | 2010 | 1078 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2009 | 902 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2019 | 831 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2008 | 846 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 525 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 192 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2016 | 230 | 0.030 |
Why?
|
| Swine | 1 | 2014 | 352 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2013 | 132 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 266 | 0.030 |
Why?
|
| Length of Stay | 2 | 2009 | 775 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 676 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 306 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2010 | 48 | 0.020 |
Why?
|
| Cetuximab | 1 | 2010 | 7 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2010 | 40 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2010 | 55 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 223 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 146 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2010 | 144 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2010 | 100 | 0.020 |
Why?
|
| Treatment Refusal | 1 | 2009 | 54 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2009 | 31 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2010 | 211 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 409 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2010 | 289 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 396 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 219 | 0.020 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2007 | 33 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 674 | 0.020 |
Why?
|
| Pigmentation | 1 | 2007 | 25 | 0.020 |
Why?
|
| Europe | 1 | 2007 | 184 | 0.020 |
Why?
|
| Canada | 1 | 2007 | 147 | 0.020 |
Why?
|
| Minocycline | 1 | 2007 | 24 | 0.020 |
Why?
|
| Mutation | 1 | 2015 | 2455 | 0.020 |
Why?
|
| Acne Vulgaris | 1 | 2007 | 23 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 2009 | 170 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2007 | 241 | 0.020 |
Why?
|
| Adolescent | 2 | 2007 | 5824 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2009 | 716 | 0.020 |
Why?
|
| Young Adult | 1 | 2016 | 4267 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 839 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2010 | 683 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2009 | 489 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2007 | 745 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2010 | 850 | 0.010 |
Why?
|
| Decision Making | 1 | 2007 | 395 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 527 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 1479 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2005 | 277 | 0.010 |
Why?
|
| Massachusetts | 1 | 2008 | 2003 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2002 | 188 | 0.010 |
Why?
|
| Hospitalization | 1 | 2007 | 1290 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 1464 | 0.010 |
Why?
|